Fewer than a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.
According to estimates, over two billion are projected to be obese by 2030 if no action is taken.
"Our new guidance affirms that obesity is a long-term condition that can be managed with comprehensive and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to universal availability to the jabs that can help people shift considerable body mass, says the organization.
GLP-1 Therapy Shortage
Despite the present most favorable case, the production of GLP-1 therapies could only cover about 100 million people – under 10% of eligible patients, according to the WHO.
The guideline encourages governments and firms to expand access, by measures like patent sharing.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Function
These medications mimick a biological compound to reduce digestion speed, curb appetite and increase the sense of being full so users consume fewer calories.
Patients usually start to lose weight within a few weeks of beginning the regular doses.
Research points to users may regain a significant portion after a year of discontinuing the drug, as their usual food cravings return.
To be above a healthy weight elevates your likelihood for contracting health problems, like diabetes, heart disease, stroke, and certain malignancies.
Obesity concerns individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
